Central Middlesex Hospital

Running trials

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· Source

• Recruiting

  A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  NCT07144137· Source

• Recruiting

  Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Phase 3· Source

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting
• Diabetic eye disease1 recruiting
• Sickle cell disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Source

• Completed

  A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

  NCT05075824· Phase 2· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· Source